EcoDrugPlus

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSBMSG00010021775
Gene Symbol: PSMB3
1 Cross references
251 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSBMSG00010017161
Gene Symbol: PSMB4
1 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSBMSG00010010731
Gene Symbol: PSMB5
1 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSBMSG00010019960
Gene Symbol: PSMB6
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSBMSG00010002486
Gene Symbol: PSMB7
1 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSBMSG00010011493
Gene Symbol: PSMB8
1 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSBMSG00010011462
Gene Symbol: PSMB9
1 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSBMSG00010007497
Gene Symbol: PSMD2
1 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSBMSG00010009924
Gene Symbol: PSMC1
1 Cross references
316 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSBMSG00010010071
Gene Symbol: PSMC2
1 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSBMSG00010021968
Gene Symbol: PSMC3
1 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSBMSG00010020303
Gene Symbol: PSMC4
1 Cross references
199 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).